| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 64
| Issue : 3 | Page : 115-124 |
|
|
Pulmonary arterial hypertension and flavonoids: A role in treatment
Jialing Wang1, Hailong Li2, Tian Xia1, Jun Feng1, Ru Zhou3
1 Department of Pharmacology, College of Pharmacy, Ningxia Medical University, Yinchuan, China
2 The Third People's Hospital of Ningxia, Yinchuan, China
3 Department of Pharmacology, College of Pharmacy; Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education; Ningxia Characteristic Traditional Chinese Medicine Modernization Engineering Technology Research Center, Ningxia Medical University, Yinchuan, China
Correspondence Address:
Prof. Ru Zhou
Department of Pharmacology, College of Pharmacy, Ningxia Medical University, 1160 Shengli street, Yinchuan 750004
China
 Source of Support: None, Conflict of Interest: None  | 4 |
DOI: 10.4103/cjp.cjp_25_21
|
|
|
Pulmonary arterial hypertension (PAH) is a high mortality progressive pulmonary vascular disease that can lead to right heart failure. The use of clinical drugs for the treatment of PAH is limited to a great extent because of its single target and high price. Flavonoids are widely distributed in nature, and have been found in fruits, vegetables, and traditional Chinese medicine. They have diverse biological activities and various pharmacological effects such as antitumor, antioxidation, and anti-inflammatory. This review summarizes the progress in pharmacodynamics and mechanism of flavonoids in the treatment of PAH in recent years, in order to provide some theoretical references for relevant researchers.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
